



## **Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences**

Waltham, Mass. – August 31, 2011 – [Syndax Pharmaceuticals, Inc.](http://www.syndax.com), a clinical-stage epigenetics oncology company, announced today that management will present at the following upcoming fall financial conferences:

- Robert W. Baird Healthcare Conference, New York, NY, September 8 at 8:30 AM ET
- Sach's 11<sup>th</sup> Annual Biotech in Europe Investor Forum, Zurich, Switzerland, September 13, 11:15 AM CEST oncology panel and 12:15 PM CEST corporate presentation
- UBS Global Life Sciences Conference, New York, NY, September 19 at 4:00 PM ET
- Sofinnova BioPartnering Conference 2011, Tokyo, Japan, October 4, time to be determined. Please visit <http://www.sofinnovajapanpartnering.com/program.php> for the schedule.
- 10<sup>th</sup> Annual BIO Investor Forum, San Francisco, CA, October 25 to 26, exact date and time to be determined. Please visit <http://www3.bio.org/investorforum/presenting-companies/2011/> for the schedule.

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit [www.syndax.com](http://www.syndax.com).

### **Contact Information**

E. Blair Schoeb  
Syndax Pharmaceuticals, Inc  
Tel: 908-277-0386  
[bschoeb@syndax.com](mailto:bschoeb@syndax.com)

###